The results for Rio 2016 Men’s 100m sprint in Athletics are in! Congratulations to reigning champion Usain Bolt of Jamaica on his gold medal, Justin Gatlin of the United States on his silver medal and Canada’s Andre De Grasse on his bronze medal. In celebration of the track and field events happening this week in the Olympic games, the above video is an interview between the Balancing Act and USA track and field champion Carl Brown about the athlete’s fight with rheumatoid arthritis. Brown works with the Arthritis Foundation to keep Americans with arthritis in motion. Continue reading
When American Olympic gold medal cyclist Kristin Armstrong was diagnosed with osteoarthritis in her hips in 2001, she decided to focus on cycling. She is the second American woman to win a gold medal in cycling. Besides cycling, Armstrong does an exercise routine that involves stretching and yoga to keep her arthritis pain at bay.
Low-impact exercises are the best types of exercise for people living with arthritis. Examples of low-impact exercises include swimming, walking, and cycling. These sports are less stressful to weight-bearing joints, especially the spine, hips, feet, knees and ankles.
If you are inspired by the Cycling Road event happening today at the Rio 2016 Olympics and would like to try cycling for yourself, here are some tips to optimize your cycling experience: Continue reading
Tofacitinib (Xeljanz®) for the treatment of rheumatoid arthritis approved in Ontario.
As of June 17th, tofacitinib (Xeljanz®) for the treatment of moderate to severe rheumatoid arthritis has been listed for coverage on Ontario’s drug formulary.
Tofacitinib is an oral targeted small molecule medicine (TSMM) that was issued a Notice of Compliance (NOC) from Health Canada on April 17, 2014. Tofacitinib in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of RA, in adult patients with moderately to severely active RA who have had an inadequate response to MTX. In cases of intolerance to MTX, physicians may consider the use of tofacitinib as monotherapy.
Click here to view the most up-to-date version of ACE’s Report Card on provincial formulary reimbursement listings for biologic response modifiers.
In this issue of JointHealth™ insight, Arthritis Consumer Experts (ACE) maps out the latest news for you about provincial drug formulary listing decisions. It contains information about important changes to provincial drug formularies and what it means for Canadians living with inflammatory arthritis. The changes covered in this update affect people living with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and juvenile idiopathic arthritis (JIA).
The following medication has been listed for reimbursement on the provincial drug formulary: Continue reading
State of Arthritis Medications: Some old, some new, all important
The reliable, quick reference arthritis medications guide you need to assist you and your health care team with your therapy conversations.
The JointHealth™ Medications Guide gives you information on the most commonly prescribed medications for inflammatory types of arthritis and osteoarthritis. Medication information for the following diseases is included in this year’s guide: rheumatoid arthritis, ankylosing spondylitis, juvenile arthritis, psoriatic arthritis, systemic lupus erythematosus, vasculitis, osteoarthritis, and osteoporosis.
In this JointHealth™ insight, you will also find:
- An explanation of the naming changes in the different categories of
- Insight into the patient-physician therapy conversation by Cheryl Koehn, Founder and President of Arthritis Consumer Experts
- Updated disease information for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile arthritis, and lupus
- The latest research on methotrexate and the consumption of alcoholic beverages
A recent study suggest that steroid use may be associated with fractures in early rheumatoid arthritis (RA). Researchers looked at the impact of systemic glucocorticoid exposure on fracture risk among new-onset rheumatoid arthritis by looking at administrative claims data between 2005-2012. The data provided detailed information about the treatments and outcomes of 42, 127 newly diagnosed RA patients.
From the data, researchers concluded that 85% of RA patients were exposed to steroids. Rheum Now summarised the research findings as follow: “Although exposed and unexposed patients were demographically similar, fracture risk was significantly higher at doses <15mg/day (5 to 9 per 1000 person-years), ≥15 mg/day (16 per 1000 PY), and with cumulative doses ≥5400 mg (13.4 per 1000 PY). Adjusted fracture risk was approximately 2-fold higher at highest dose levels compared with 0 mg/day current daily dose and <675 mg cumulative dose, respectively.” Continue reading